160 related articles for article (PubMed ID: 38301010)
21. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Shaffer AL; Phelan JD; Wang JQ; Huang D; Wright GW; Kasbekar M; Choi J; Young RM; Webster DE; Yang Y; Zhao H; Yu X; Xu W; Roulland S; Ceribelli M; Zhang X; Wilson KM; Chen L; McKnight C; Klumpp-Thomas C; Thomas CJ; Häupl B; Oellerich T; Rae Z; Kelly MC; Ahn IE; Sun C; Gaglione EM; Wilson WH; Wiestner A; Staudt LM
Blood Cancer Discov; 2021 Nov; 2(6):630-647. PubMed ID: 34778802
[TBL] [Abstract][Full Text] [Related]
22. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Gu D; Tang H; Wu J; Li J; Miao Y
J Hematol Oncol; 2021 Mar; 14(1):40. PubMed ID: 33676527
[TBL] [Abstract][Full Text] [Related]
23. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
[TBL] [Abstract][Full Text] [Related]
24. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Lampson BL; Brown JR
Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
[TBL] [Abstract][Full Text] [Related]
25. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
26. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
27. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
28. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
[TBL] [Abstract][Full Text] [Related]
29. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Woyach JA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
[No Abstract] [Full Text] [Related]
32. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
[TBL] [Abstract][Full Text] [Related]
34. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
35. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
37. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
[TBL] [Abstract][Full Text] [Related]
38. New means and challenges in the targeting of BTK.
Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38578606
[TBL] [Abstract][Full Text] [Related]
39. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
[TBL] [Abstract][Full Text] [Related]
40. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Dobrovolsky D; Wang ES; Morrow S; Leahy C; Faust T; Nowak RP; Donovan KA; Yang G; Li Z; Fischer ES; Treon SP; Weinstock DM; Gray NS
Blood; 2019 Feb; 133(9):952-961. PubMed ID: 30545835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
